NYSE:EW

73.32
0.65 (0.88%) 1d
0

Related posts

Hot Meta, hot jobs report
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

The reviews from different experts on the stock of Edwards Lifesciences Corp (EW-N) indicate a significant single-day drop of 30%, the worst since 2000, which has led to a punishing effect on the stock. Despite the drop, the stock is still at a high multiple of 25x post-drop. This indicates that earnings misses are being punished due to the high aggregate multiple they trade at. The market sentiment seems to be cautious and watchful of the stock's performance in the coming days.

Consensus
Cautious
Valuation
Overvalued
COMMENT
Down 30% today, the worst single-day drop since 2000. Very punishing.

The interesting is that it's still at 25x post-drop. You're seeing earnings misses get punished because the aggregate multiple they trade at is still on the high end.

biotechnology / pharmaceutical
DON'T BUY

That had a terrible quarter. They must do better.

biotechnology / pharmaceutical
BUY

Reported a solid quarter and guidance in last April. Is up 20% YTD, but has more room to run. He's bullish medical devices.

biotechnology / pharmaceutical
DON'T BUY
Structural heart disease drugs. Must distinguish between quality stocks. This is one. However, it is less attractive due to the valuation. Future success is already priced in.
biotechnology / pharmaceutical
BUY ON WEAKNESS
It's a reopening play and the stock is down, more reason to pick it up.
biotechnology / pharmaceutical
COMMENT

He has owned IRTC-O in the past. It is in the medical device space and has equipment that looks for heart arrhythmia and loads the data to the cloud. The market has not yet said this stock has taken a positive turn yet. Earnings are growing and it is growing into its share price. He wants to see it break above $85-$87 before getting back in. He would prefer holding EW-N

biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Mar 19/18, Up 22%) He owns this through the IHI ETF. Their catheter device accounts for 60% of revenue and results in less-invasive surgeries which results in higher patient turnover in hospitals (which are expensive). This is better for patients and hospitals. They continue to take market share.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Feb 08/18, Up 37%) A high-quality holding, who's business is less evasive surgery technology. They have massive market share in the space. Lots of spending by hospitals will go into this. You have to accept it will be volatile at times.
biotechnology / pharmaceutical
DON'T BUY

When it came down to his model price it was the only buying opportunity there was in the last eight years. He loves the company. Model price is $99.94, a 30% premium that it is trading at. He can only wish for a pull back.

biotechnology / pharmaceutical
TOP PICK

Trans-catheter aortic valve replacement is their business, a best in class valve that's been taken up widely in hospitals around the world. This market will double in three years, and they are the big player. (Analysts' target of $142.80)

biotechnology / pharmaceutical
TOP PICK

Valve replacement. They have trans catheter valve replacements. It is done in the least invasive way that the medical space has come up with. It is all very positive. They are well placed in a growing part of the healthcare market. It is expected to double by 2021. (Analysts’ target: $142.).

biotechnology / pharmaceutical
COMMENT

Very focused on cardiovascular and ICU. The great thing about this is that the demand is very inelastic, so you get the unit demand independent of the economic cycle, a good solid demand. Also, they are innovators and have good research and good product flow on their own and have been smart acquirers.

biotechnology / pharmaceutical
TOP PICK
Primarily involved in cardiovascular products. Half the business is in heart valve therapy with about 45% of market share. Have some new products that could create new markets for them and this hasn't been priced into the stock.
biotechnology / pharmaceutical
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »

Edwards Lifesciences Corp(EW-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Edwards Lifesciences Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Edwards Lifesciences Corp(EW-N) Frequently Asked Questions

What is Edwards Lifesciences Corp stock symbol?

Edwards Lifesciences Corp is a American stock, trading under the symbol EW-N on the New York Stock Exchange (EW). It is usually referred to as NYSE:EW or EW-N

Is Edwards Lifesciences Corp a buy or a sell?

In the last year, there was no coverage of Edwards Lifesciences Corp published on Stockchase.

Is Edwards Lifesciences Corp a good investment or a top pick?

Edwards Lifesciences Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Edwards Lifesciences Corp.

Why is Edwards Lifesciences Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Edwards Lifesciences Corp worth watching?

0 stock analysts on Stockchase covered Edwards Lifesciences Corp In the last year. It is a trending stock that is worth watching.

What is Edwards Lifesciences Corp stock price?

On 2024-12-13, Edwards Lifesciences Corp (EW-N) stock closed at a price of $73.32.